Dominari Holdings Crecimiento futuro

Future controles de criterios 0/6

Actualmente no disponemos de suficiente cobertura de analistas para prever el crecimiento y los ingresos de Dominari Holdings.

Información clave

n/a

Tasa de crecimiento de los beneficios

n/a

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	24.4%
Tasa de crecimiento de los ingresos	n/a
Rentabilidad financiera futura	n/a
Cobertura de analistas	None
Última actualización	n/a

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Here's Why We're Not Too Worried About AIkido Pharma's (NASDAQ:AIKI) Cash Burn Situation

Sep 29

We Think AIkido Pharma (NASDAQ:AIKI) Can Easily Afford To Drive Business Growth

Jun 05

AIkido Pharma's stock surges on psilocybin patent license agreement

Jan 06

En esta sección solemos presentar previsiones de crecimiento de ingresos y beneficios basadas en las estimaciones por consenso de analistas profesionales para ayudar a los inversores a comprender la capacidad de la empresa para generar beneficios. Pero como Dominari Holdings no ha proporcionado suficientes datos anteriores y no dispone de previsiones de analistas, sus beneficios futuros no pueden calcularse de forma fiable extrapolando datos anteriores o utilizando las previsiones de los analistas.

Es una situación poco común, ya que el 97% de las empresas disponibles en SimplyWall St sí disponen de datos financieros anteriores.

Previsiones de crecimiento de beneficios e ingresos

NasdaqCM:DOMH - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
3/31/2024	3	-25	-27	-27	N/A
12/31/2023	2	-23	-23	-22	N/A
9/30/2023	1	-23	-21	-19	N/A
6/30/2023	0	-26	-21	-19	N/A
3/31/2023	N/A	-23	-13	-11	N/A
12/31/2022	N/A	-26	-12	-11	N/A
9/30/2022	N/A	-21	-11	-11	N/A
6/30/2022	N/A	-15	-10	-10	N/A
3/31/2022	N/A	-10	-9	-9	N/A
12/31/2021	N/A	-7	-7	-7	N/A
9/30/2021	N/A	-5	-6	-5	N/A
6/30/2021	N/A	-7	-5	-4	N/A
3/31/2021	N/A	-8	-5	-4	N/A
12/31/2020	N/A	-12	-5	-4	N/A
9/30/2020	0	-12	-6	-4	N/A
6/30/2020	0	-13	-5	-4	N/A
3/31/2020	0	-11	-5	-4	N/A
12/31/2019	0	-4	-3	-3	N/A
9/30/2019	0	0	-3	-3	N/A
6/30/2019	0	2	-3	-3	N/A
3/31/2019	0	2	-3	-3	N/A
12/31/2018	0	2	-3	-3	N/A
9/30/2018	0	-5	-3	-3	N/A
6/30/2018	1	-2	-3	-3	N/A
3/31/2018	1	-4	-4	-4	N/A
12/31/2017	1	-3	N/A	-3	N/A
9/30/2017	1	-6	N/A	-3	N/A
6/30/2017	1	-7	N/A	-4	N/A
3/31/2017	1	25	N/A	1	N/A
12/31/2016	1	25	N/A	0	N/A
9/30/2016	1	34	N/A	0	N/A
6/30/2016	0	31	N/A	0	N/A
3/31/2016	0	-39	N/A	-5	N/A
12/31/2015	0	-42	N/A	-5	N/A
9/30/2015	0	-53	N/A	-8	N/A
6/30/2015	0	-55	N/A	-9	N/A
3/31/2015	0	-27	N/A	-9	N/A
12/31/2014	0	-31	N/A	-10	N/A
9/30/2014	0	-29	N/A	-6	N/A
6/30/2014	0	-33	N/A	-7	N/A
3/31/2014	0	-22	N/A	-6	N/A
12/31/2013	0	-18	N/A	-5	N/A
9/30/2013	0	-15	N/A	-5	N/A
6/30/2013	0	-6	N/A	-4	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Datos insuficientes para determinar si el crecimiento previsto de los beneficios de DOMH es superior a la tasa de ahorro (2.3%).

Beneficios vs. Mercado: Datos insuficientes para determinar si se prevé que los beneficios de DOMH crezcan más rápidamente que el mercado US

Beneficios de alto crecimiento: Datos insuficientes para determinar si se espera que los beneficios de DOMH crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: No hay datos suficientes para determinar si se prevé que los ingresos de DOMH crezcan más rápidamente que el mercado de US.

Ingresos de alto crecimiento: No hay datos suficientes para determinar si se prevé que los ingresos de DOMH crezcan a un ritmo superior a 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de DOMH se prevé que sea elevada dentro de 3 años.

Dominari Holdings Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target decreased to US$16.00

Recent updates

New minor risk - Share price stability

CEO & Chairman recently bought US$140k worth of stock

Dominari Holdings Inc. Announces Appointment of Mr. Kyle Wool as President

New minor risk - Shareholder dilution

Dominari Holdings Inc. Announces Executive Changes

New major risk - Market cap size

Dominari Holdings Inc. Announces Resignation of Paul Lemire as Member of the Board of Directors and Member of Audit Committee, Compensation Committee, and Nominating Committee

Dominari Holdings Inc. Announces Management Changes

New minor risk - Shareholder dilution

Dominari Holdings Inc., Annual General Meeting, Sep 21, 2023

New major risk - Financial position

Dominari Holdings Inc. Appoints Kyle Wool as CEO of Dominari Securities LLC

Dominari Holdings Inc. Appoints Matthew B. McCullough as the General Counsel

CEO, Principal Financial Officer recently bought US$103k worth of stock

Dominari Holdings Inc. Appoints Christopher Devall as Chief Operating Officer

AIkido Pharma Inc.(NasdaqCM:DOMH) dropped from NASDAQ Composite Index

AIkido Pharma Inc. (NasdaqCM:AIKI) announces an Equity Buyback for $2 million worth of its shares.

Price target decreased to US$16.00

High number of new directors

AIkido continues to buyback more shares

AIkido Pharma's subsidiary agrees to buy broker-dealer firm

Shalom Auerbach made an offer to acquire additional 96.2% stake in AIkido Pharma Inc. (NasdaqCM:AIKI) for $40.4 million.

Alkido Pharma shareholders proposes to acquire company at $8/share in cash

High number of new directors

AIkido Pharma Regains Compliance with NASDAQ Listing Requirements

AIkido Pharma Inc. Appoints Soo Yu as Director

Shalom Auerbach Issues an Open Letter to Board of Directors of AIkido Pharma

AIkido Pharma Inc. (NasdaqCM:AIKI) acquired an unknown stake in Databricks, Inc.

AIkido Pharma (NASDAQ:AIKI) Is In A Good Position To Deliver On Growth Plans

High number of new and inexperienced directors

AIkido Pharma Inc., Annual General Meeting, May 16, 2022

AIkido Pharma Inc. Reports Improved Manufacturing Process and New United States Patent for Pancreatic Drug

AIkido Pharma: Advancing Anticancer And Antiviral Therapies

AIkido Pharma Inc. (NasdaqCM:AIKI) announces an Equity Buyback for $3 million worth of its shares.

AIkido Pharma (NASDAQ:AIKI) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Not Too Worried About AIkido Pharma's (NASDAQ:AIKI) Cash Burn Situation

Aikido Pharma Files Patent Application for the Use of Ketamine to Treat Alzheimer's Disease

We Think AIkido Pharma (NASDAQ:AIKI) Can Easily Afford To Drive Business Growth

AIkido Pharma Inc. Announces Phase 1 Data to Be Presented at the American Society of Clinical Oncology Annual Meeting

Aikido Pharma Provides Update on Its Antiviral Platform, Including the Virus That Causes COVID-19

New 90-day high: US$1.91

Aikido Pharma Inc. Appoints Scott T. Tagawa, M.D. to Scientific Advisory Board

AIkido Pharma Inc. Appoints Neil H. Bander as Company's Scientific Advisory Board

New 90-day high: US$1.21

AIkido Pharma Inc. Executes Licensing Agreement for Psilocybin for Cancer Applications

AIkido Pharma's stock surges on psilocybin patent license agreement

New 90-day high: US$0.73

AIkido Pharma Inc. Announces Publication of Artificial Intelligence-Machine Learning Sponsored Research Program for Pancreatic Cancer

New 90-day high: US$0.67

Aikido Pharma Inc. Announces Publication of Positive Results from A Study of Antiviral Activity of FDA Approved Drugs

New 90-day low: US$0.54

New 90-day low: US$0.55

New 90-day high - US$1.23

Earnings released

AIkido Pharma Regains Compliance with NASDAQ Minimum Bid Price Listing Requirements

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento